Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.

e18796Background: There is limited evidence supporting the optimal use of immune checkpoint inhibitors (ICIs) in NSCLC patients with poor performance status (PS), as clinical trials exclude these p...